Cullinan Management (CGEM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from JonesTrading maintained a Buy rating on the stock and has a $34.00 price target.
Soumit Roy’s rating is based on the promising potential of Cullinan Management’s CD19xCD3 TCE, which is highlighted by the recent Phase 3 data from Amgen’s MINT trial. The trial demonstrated significant improvements in patients with AChR+ generalized myasthenia gravis, underscoring the effectiveness of targeting CD19 in treating immune and inflammatory diseases.
Furthermore, Cullinan’s ongoing Phase 1 trial with CLN-978 for systemic lupus erythematosus, with results expected in the fourth quarter of 2025, adds to the company’s potential for future growth. The scarcity value of Cullinan’s CD19-targeting therapies further supports the Buy rating, as it positions the company uniquely in the market.
Roy covers the Healthcare sector, focusing on stocks such as Chimerix, Day One Biopharmaceuticals, and Oric Pharmaceuticals. According to TipRanks, Roy has an average return of -23.4% and a 16.73% success rate on recommended stocks.
In another report released on March 7, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $35.00 price target.